Project Bioshield, the federal bioterrorism preparedness program that’s yielded vaccines effective against anthrax and Ebola, heads into its third decade anticipating threats far different from those ...
Sign in to create a free account. No password needed. Enter your email and we’ll send a secure one-click link to sign in. Please enter a valid email address By clicking on any of the sign up options ...
WASHINGTON -- Lawmakers who experienced the dangers of anthrax firsthand sent President Bush legislation Wednesday to give private companies $5.6 billion in incentives to develop antidotes to ...
Project BioShield: Consistent financing, markets, indemnity for biodefense vaccine developers needed
WASHINGTON, DC (April 4, 2003): Biotechnology companies are well suited to address the modest commercial opportunities offered by creating safer, more effective and less costly vaccines for biodefense ...
MALVERN, Pa.--(BUSINESS WIRE)--Venatorx Pharmaceuticals, a private, late-stage clinical pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial ...
Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats Program Includes Establishing Pharmaceutical ...
Federal public health officials said Thursday that they anticipate Congress will soon pass the Project Bioshield legislation, a sweeping bill designed to strengthen the nation's biological defenses ...
SAN DIEGO - When President Bush signed Project BioShield into law in July, he said he was immediately making $5.6 billion available to counter such anticipated threats as smallpox genetically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results